Celltrion Rebounds from First-Half Slump, Eyes Strong Performance in Second Half [Click e-Stock]

Record-High Second Quarter Performance
Continued Growth Expected for High-Margin New Products in the Second Half

In the second quarter of this year, Celltrion delivered results that met market expectations. The company is expected to aim for earnings growth in the second half of the year by launching new high-margin products and reducing the proportion of high-cost inventory.

On July 22, NH Investment & Securities maintained its target price for Celltrion at 230,000 won and its "Buy" investment opinion, citing these factors. The previous day's closing price was 181,200 won.

In the second quarter of this year, on a consolidated basis, Celltrion recorded sales of 961.5 billion won and operating profit of 242.5 billion won. These figures represent increases of 9.9% and 234.5%, respectively, compared to the same period last year. The results are in line with market consensus, which expected sales of 990.7 billion won and operating profit of 244.9 billion won. This also marks the highest second-quarter performance in the company's history.

Among its biopharmaceutical products, Tier 1 product sales reached 414.8 billion won, while Tier 2 product sales totaled 476.8 billion won. For the first time, the proportion of Tier 2 sales exceeded 50%, leading to a significant improvement in the quarterly operating margin to 25.2%, up from 17.7% in the previous quarter.

In the second half of this year, four new products, including Omriclo and Aptozma, are scheduled for launch, and growth in high-margin new products is expected to continue. In addition, the proportion of high-cost inventory is steadily declining, and further improvement in the cost ratio is anticipated due to the full-scale ramp-up of IT production in the second half, the completion of amortization for Remsima development costs, and the exclusion of DS contract manufacturing costs.

Han Seungyeon, a researcher at NH Investment & Securities, stated, "Since March, the stock price correction has been due to concerns about earnings and uncertainty regarding U.S. pharmaceutical tariffs." He added, "The recent rebound in the stock price has been driven by expectations that these issues will be resolved, and for a sustained upward trend going forward, growth in operating profit and the success of new growth strategies are necessary."

This content was produced with the assistance of AI translation services.